Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Developing Efficacious, Stable & Safe High-DAR Mono & Dual Payload ADCs via Modular Multi-Arm Drug Bundle Technology & Flexible Conjugation

By | 8 June 2026

Exploring stabilized linker designs and optimized dual payload combinations to enhance ADC stability, efficacy, and overcome drug resistance
Assessing flexible conjugation methods through thiol maleimide and copper free click chemistries to allow precise drug bundle attachment and optimal DAR
Explaining how site-specific conjugation of drug bundles enables high-DAR mono and dual payload ADCs with superior efficacy, stability and safety